Latest Breaking News On - Frontline pembrolizumab plus chemotherapy - Page 1 : comparemela.com

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

Manisha shahSolid tumor serviceGastrointestinal oncology programWeill cornell medicineAdvanced digestive diseaseNewyork presbyterianKeynote 590 trialFrontline pembrolizumab plus chemotherapyPatients with esophageal cancer